- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on PD-L1 Amplified Tumor (9p24.1)
Total 64 results
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.UnknownRecurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant TumorsChina
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Hoffmann-La RocheRecruitingPD-L1-selected Solid TumorsKorea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Baodong QinUnknown
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Consorzio OncotechCompletedMetastatic or Locally Advanced PD-L1 Positive Urothelial CancerItaly
-
Peking University Cancer Hospital & InstituteRecruitingMelanoma | Lung Cancer | PD-L1 | PET/CTChina
-
Novartis PharmaceuticalsRecruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationItaly, Spain, United States, France, Thailand, Malaysia, China, Germany, India, Turkey, Belgium, Argentina, Bulgaria, Netherlands, Hungary, Greece, Portugal, Austria, Singapore, Brazil, United Kingdom
-
Shanghai Zhongshan HospitalRecruitingCholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4China
-
Institute of Oncology LjubljanaUniversity of Ljubljana; Military Medical Academy, Belgrade, SerbiaRecruitingMetastatic Melanoma | Immune Checkpoints Inhibitors | Gastrointestinal Microbiome (Bacterial and Viral) | Exosomal mRNA Expression of PD-L1 and IFNγSlovenia
-
Incyte CorporationRecruitingCervical Cancer | Nasopharyngeal Carcinoma | Mesothelioma | Advanced Solid Tumor | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | HepatoCellular Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1)United States, Japan, France, Belgium, Australia
-
Ascletis Pharmaceuticals Co., Ltd.RecruitingHIV Infections | HIV-1-infection | PD-L1 Gene MutationChina
-
Maastricht Radiation OncologyCompletedProstate Cancer | PD-L1Netherlands
-
Sarah GoldbergMirati Therapeutics Inc.TerminatedLung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | SitravatinibUnited States
-
Dana-Farber Cancer InstituteMerck Sharp & Dohme LLC; Gilead SciencesRecruitingBreast Cancer | Triple Negative Breast Cancer | PD-L1 NegativeUnited States
-
Gilead SciencesRecruitingTriple Negative Breast Cancer | PD-L1 NegativeUnited States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
Shanghai International Medical CenterUnknownAdvanced Solid Tumor | PD-1 Antibody | CAR-T CellsChina
-
Kidney Cancer Research BureauRecruitingMetastatic Gastric Cancer | FGFR2 Amplification | PD-L1 Gene AmplificationUnited States
-
Consorzio OncotechActive, not recruitingMetastatic Breast Cancer | Triple Negative Breast Cancer | PD-L1 Gene MutationItaly
-
Shirish M GadgeelAstraZeneca; Henry Ford Health SystemWithdrawnLung Cancer | Non-small Cell Lung Cancer | PD-L1 Gene Mutation | KRAS Activating MutationUnited States
-
Shanghai Cancer Hospital, ChinaUnknownLung Cancer Stage IV,EGFR-mutant,TKI,PD-L1,SBRTChina
-
Ambrx, Inc.WithdrawnHER2 Mutation-Related Tumors | HER2 Amplified Solid TumorsUnited States
-
Poitiers University HospitalActive, not recruitingNon Small Cell Lung Cancer | Gene Mutation-Related Cancer | PD-L1 | PET/CTFrance
-
University of Colorado, DenverCancer League of ColoradoWithdrawnMetastatic Breast Cancer | Triple Negative Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | PD-L1 Gene MutationUnited States
-
Lei LiRecruitingMicrosatellite Instability | Recurrent Cervical Cancer | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Xiaorong DongUnknown
-
Xiaohua ZhuRecruitingNSCLC Stage IV | PD-L1 Gene AmplificationChina
-
The First Hospital of Jilin UniversityRecruitingPD-L1 Positive Locally Advanced Patients With Resectable Gastric CancerChina
-
Novartis PharmaceuticalsNantCell, Inc.TerminatedPIK3CA Mutated Advanced Solid Tumors | PIK3CA Amplified Advanced Solid TumorsSpain, Belgium, United States, Canada
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingRecurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
-
Merrimack PharmaceuticalsCompletedMetastatic Breast Cancer | Her2 Amplified Solid TumorsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb; National Cancer Institute (NCI)RecruitingRefractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy | MSI-H TumorsUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Incyte CorporationActive, not recruitingCervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditionsFinland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerBelgium, United States, Poland, India, Taiwan, Thailand, Korea, Republic of, Czechia, Russian Federation, United Kingdom, Spain, Australia, Canada, Italy, Netherlands
-
Tongji HospitalZhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaboratorsNot yet recruitingCervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant ChemoimmunotherapyChina
-
Ascendis Pharma Oncology Division A/SRecruitingAdvanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...United States, Australia, Korea, Republic of
-
Sun Yat-sen UniversityRecruitingInduction Chemotherapy | Locally Advanced Nasopharyngeal Carcinoma | PD-L1 | EnvafolimabChina
-
University of MinnesotaChildren's Cancer Research Fund United StatesTerminatedLymphoblastic Lymphoma | Brain Tumors | Lymphoblastic Leukemia, Acute, Childhood | Lymphoblastic Leukemia | Leukemia, Lymphocytic, Acute | Leukemia, Lymphoblastic, Acute | Brain Neoplasms, Malignant | ALL, Childhood | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Lymphoblastic Leukemia, Acute | Leukemia... and other conditionsUnited States
-
Shirish GadgeelMerck Sharp & Dohme LLCWithdrawnNon Small Cell Lung Cancer | PD-L1 Gene Mutation | Advanced Lung Non-Small Cell Carcinoma
-
Beijing Friendship HospitalNot yet recruiting
-
Peking UniversityUnknownPatients With Digestive System Tumors Resistant to PD-1 Inhibitors
-
Lei LiRecruitingEpithelial Ovarian Cancer | Microsatellite Instability | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Istituto Scientifico Romagnolo per lo Studio e...RecruitingProgressive Disease | Mesothelioma, Malignant | Advanced Cancer | PD-L1 NegativeItaly
-
University Hospital HeidelbergDepartment of Dermatology, Heidelberg University HospitalCompletedMelanoma | Exercise | PD-1 AntibodiesGermany